Gut Microbiome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Insights into Disease Mechanisms.
Nikolova, Ralitsa, Donchev, Deyan, Vaseva, Katya et al. · International journal of molecular sciences · 2025 · DOI
Quick Summary
This review examines the connection between gut bacteria and ME/CFS, a condition characterized by exhaustion that worsens after activity. The authors explain how an imbalance in gut bacteria may damage the intestinal barrier, allowing bacterial particles to enter the bloodstream and trigger inflammation throughout the body. They also discuss how changes in gut bacteria might affect the brain, contributing to the brain fog and cognitive problems many ME/CFS patients experience.
Why It Matters
Understanding the gut microbiome's role in ME/CFS is important because it may explain multiple symptoms patients experience and could lead to new diagnostic approaches and treatments. This review brings together evidence suggesting that targeting gut dysbiosis through dietary or probiotic interventions might help reduce inflammation and improve symptoms in ME/CFS patients.
Observed Findings
- Dysbiosis (imbalanced gut bacteria composition) is frequently documented in ME/CFS patients compared to healthy controls
- Impaired intestinal barrier integrity allows bacterial components to enter the bloodstream and trigger immune responses
- Altered microbiome composition may influence neurotransmitter production and contribute to cognitive symptoms
- Systemic inflammation markers correlate with dysbiosis severity in some ME/CFS populations
- Microbiome-targeted interventions (dietary modifications, probiotics) show potential in preliminary studies
Inferred Conclusions
- Dysbiosis may be a contributing mechanism in ME/CFS pathophysiology through intestinal barrier dysfunction and immune activation
- The gut-brain axis likely mediates some neurological and cognitive symptoms observed in ME/CFS
- Microbiome-focused therapeutic strategies warrant further investigation as potential adjunctive treatments
- Multiple interconnected mechanisms (immune, metabolic, neurological) involving the microbiome may explain the heterogeneous clinical presentation of ME/CFS
Remaining Questions
- Does dysbiosis cause ME/CFS or result from it, and what is the temporal relationship between microbiome changes and disease onset?
- Which specific bacterial taxa or functional profiles are most relevant to disease mechanisms and could serve as diagnostic or prognostic biomarkers?
- What is the optimal microbiome-targeted intervention strategy, and which ME/CFS patient subgroups are most likely to benefit?
- How do individual genetic and immunological factors interact with microbiome composition to determine disease severity and response to treatment?
What This Study Does Not Prove
This systematic review does not establish that dysbiosis is the primary cause of ME/CFS or prove that microbiome changes directly cause the disease in all patients. The studies reviewed show associations and propose mechanisms, but do not definitively prove causation, and individual patient responses to microbiome interventions may vary significantly.
Topics
Tags
Metadata
- DOI
- 10.3390/ijms27010425
- PMID
- 41516296
- Review status
- Editor reviewed
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 7 April 2026